Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 16/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884806 | 0.86 | KCNA5 (1.00) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL884617 | 0.84 | KCNA5 (0.95) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL2063123 | 0.80 | KCNA5 (0.82) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL884895 | 0.80 | KCNA5 (0.82) | KCNA5KCNH2LMNA | |
| SCHEMBL884543 | 0.79 | KCNA5 (0.80) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL884812 | 0.79 | KCNA5 (0.84) | KCNA5KCNH2LMNA | |
| SCHEMBL884705 | 0.79 | KCNA5 (0.84) | KCNA5KCNH2L3MBTL1 | |
| SCHEMBL885022 | 0.78 | KCNA5 (0.79) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL2062703 | 0.78 | KCNA5 (0.74) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL884612 | 0.78 | KCNA5 (0.74) | KCNA5KCNH2LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| EP-1940406-A2 | POTASSIUM CHANNEL INHIBITORS | Merck and Co., Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007050348-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | claimed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885LMNA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.